Money Matters - Simplified

How Cheap Is Tenet Healthcare's Stock?

 Numbers can lie -- yet they're the best first step in determining whether a stock is a buy. In this series, we use some carefully chosen metrics to size up a stock's true value based on the following clues:

 
  • The current price multiples.
  • The consistency of past earnings and cash flow.
  • The amount of growth we can expect.

Let's see what those numbers can tell us about how cheap hospital operator Tenet Healthcare (NYSE: THC) might be.

The current price multiples
First, we'll look at most investors' favorite metric: the price-to-earnings ratio. It divides the company's share price by its earnings per share (EPS). The lower the P/E, the better.

Then we'll take things up a notch with a more advanced metric: enterprise value to unlevered free cash flow. This tool divides the company's enterprise value (basically, its market cap plus its debt, minus its cash) by its unlevered free cash flow (its free cash flow, adding back the interest payments on its debt). As with the P/E, the lower this number is, the better.

Analysts argue about which is more important -- earnings or cash flow. Who cares? A good buy ideally has low multiples on both.

Tenet has a P/E ratio of 14.2 and an EV/FCF ratio of 23.7 over the trailing 12 months. If we stretch and compare current valuations with the five-year averages for earnings and free cash flow, we see that Tenet has a negative P/E ratio and a negative five-year EV/FCF ratio.

A one-year ratio of less than 10 for both metrics is ideal. For a five-year metric, less than 20 is ideal.

Tenet is 0-for-4 on hitting the ideal targets, but let's see how it stacks up against some of its competitors and industry mates. 

Company

1-Year P/E

1-Year EV/FCF

5-Year P/E

5-Year EV/FCF

Tenet Healthcare

14.2

23.7

NM

NM

Community Health Systems(NYSE: CYH)

10.1

14.2

15.2

21.0

Lifepoint Hospitals (Nasdaq:LPNT)

11.4

10.8

14.0

15.6

Universal Health Services(NYSE: UHS)

15.8

28.8

18.3

59.1

Source: Capital IQ, a division of Standard & Poor's; NM = not meaningful.

Numerically, we've seen how Tenet's valuation rates on both an absolute and relative basis. Next, let's examine …

The consistency of past earnings and cash flow
An ideal company will be consistently strong in its earnings and cash flow generation.

In the past five years, Tenet's net income margin has ranged from (11.9%) to 2.7%. In that same time frame, unlevered free cash flow margin has ranged from (10.8%) to 2.8%.

How do those figures compare with those of the company's peers? See for yourself:

 

In addition, over the past five years, Tenet has tallied up two years of positive earnings and two years of positive free cash flow.

Next, let's figure out …

How much growth we can expect
Analysts tend to comically overstate their five-year growth estimates. If you accept them at face value, you will overpay for stocks. But even though you should definitely take the analysts' prognostications with a grain of salt, they can still provide a useful starting point when compared with similar numbers from a company's closest rivals.

Let's start by seeing what this company's done over the past five years. Tenet's losses leave its trailing growth rate meaningless, but Wall Street's analysts expect future growth rates of 10.6%.

Here's how Tenet's peers rate for trailing five-year growth:


 And here's how it measures up with regard to the growth analysts expect over the next five years:


 The bottom line

The pile of numbers we've plowed through has shown us how cheap shares of Tenet are trading, how consistent its performance has been, and what kind of growth profile it has -- both on an absolute and a relative basis.

The more consistent a company's performance has been and the more growth we can expect, the more we should be willing to pay. We've gone well beyond looking at a 14.2 P/E ratio.

Tenet's numbers beyond that one-year trailing P/E ratio don't look nearly as good. Community Health Systems and Lifepoint Hospitals both look better purely by the numbers.

If you find any of these numbers compelling, don't stop here. Continue your due-diligence process, factoring in items such as health-care regulation, until you're confident that the initial numbers aren't lying to you.

© 2010 UCLICK L.L.C.